Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch.
Warda W, Da Rocha MN, Trad R, Haderbache R, Salma Y, Bouquet L, Roussel X, Nicod C, Deschamps M, Ferrand C. Warda W, et al. Among authors: deschamps m. Cancer Gene Ther. 2021 Dec;28(12):1365-1375. doi: 10.1038/s41417-020-00284-3. Epub 2021 Jan 7. Cancer Gene Ther. 2021. PMID: 33414517 Free PMC article.
Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance.
Bennour E, Ferrand C, Rémy-Martin JP, Certoux JM, Gorke S, Qasim W, Gaspar HB, Baumert T, Duperrier A, Deschamps M, Fehse B, Tiberghien P, Robinet E. Bennour E, et al. Among authors: deschamps m. Hum Gene Ther. 2008 Jul;19(7):699-709. doi: 10.1089/hum.2007.060. Hum Gene Ther. 2008. PMID: 18557699
Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response?
Mercier-Letondal P, Deschamps M, Sauce D, Certoux JM, Milpied N, Lioure B, Cahn JY, Deconinck E, Ferrand C, Tiberghien P, Robinet E. Mercier-Letondal P, et al. Among authors: deschamps m. Hum Gene Ther. 2008 Sep;19(9):937-50. doi: 10.1089/hum.2007.156. Hum Gene Ther. 2008. PMID: 18810797
Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance.
Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Rémy-Martin JP, Callanan M, Traverse-Glehen A, GrandClément C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C. Henry C, et al. Among authors: deschamps m. Blood. 2010 Mar 25;115(12):2420-9. doi: 10.1182/blood-2009-06-229112. Epub 2010 Jan 20. Blood. 2010. PMID: 20089966 Free article.
Incidence and risk factors of anti-HLA immunization after pregnancy.
Masson E, Vidal C, Deschamps M, Bongain S, Thevenin C, Dupont I, Rietmulher D, Pouthier F, Mongaillard G, Chabod J, Ferrand C, Tiberghien P, Rebibou JM. Masson E, et al. Among authors: deschamps m. Hum Immunol. 2013 Aug;74(8):946-51. doi: 10.1016/j.humimm.2013.04.025. Epub 2013 Apr 27. Hum Immunol. 2013. PMID: 23628391
Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.
Leboeuf C, Roser-Schilder J, Lambotin M, Durand S, Wu T, Fauvelle C, Su B, Bôle-Richard E, Deschamps M, Ferrand C, Tiberghien P, Pessaux P, Baumert TF, Robinet E. Leboeuf C, et al. Among authors: deschamps m. Gene Ther. 2015 Feb;22(2):172-80. doi: 10.1038/gt.2014.99. Epub 2014 Nov 13. Gene Ther. 2015. PMID: 25394253
288 results